After finishing at $9.09 in the prior trading day, Tango Therapeutics Inc (NASDAQ: TNGX) closed at $9.03, down -0.66%. In other words, the price has decreased by -$0.06 from its previous closing price. On the day, 3316871 shares were traded.
Ratios:
Our goal is to gain a better understanding of TNGX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.54 and its Current Ratio is at 8.54. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on February 12, 2024, initiated with a Overweight rating and assigned the stock a target price of $18.
On December 08, 2023, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $16.
H.C. Wainwright Upgraded its Neutral to Buy on October 20, 2022, while the target price for the stock was maintained at $10.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 20 ’24 when Third Rock Ventures IV, L.P. sold 162,500 shares for $12.00 per share. The transaction valued at 1,950,000 led to the insider holds 19,201,475 shares of the business.
Weber Barbara sold 4,457 shares of TNGX for $56,246 on Feb 07 ’24. The Chief Executive Officer now owns 1,535,167 shares after completing the transaction at $12.62 per share. On Feb 07 ’24, another insider, Crystal Adam, who serves as the insider of the company, sold 4,083 shares for $12.62 each. As a result, the insider received 51,527 and left with 119,478 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNGX now has a Market Capitalization of 920.97M and an Enterprise Value of 600.59M. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.55 while its Price-to-Book (P/B) ratio in mrq is 3.32. Its current Enterprise Value per Revenue stands at 16.01 whereas that against EBITDA is -5.59.
Stock Price History:
Over the past 52 weeks, TNGX has reached a high of $13.03, while it has fallen to a 52-week low of $2.47. The 50-Day Moving Average of the stock is 11.25, while the 200-Day Moving Average is calculated to be 7.94.
Shares Statistics:
The stock has traded on average 634.70K shares per day over the past 3-months and 889.79k shares per day over the last 10 days, according to various share statistics. A total of 88.18M shares are outstanding, with a floating share count of 50.15M. Insiders hold about 50.83% of the company’s shares, while institutions hold 54.50% stake in the company. Shares short for TNGX as of Feb 29, 2024 were 8.87M with a Short Ratio of 13.97, compared to 10.51M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.69% and a Short% of Float of 15.43%.
Earnings Estimates
Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of -$0.28 for the current quarter, with a high estimate of -$0.25 and a low estimate of -$0.32, while EPS last year was -$0.33. The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.28 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$1.03 and -$1.11 for the fiscal current year, implying an average EPS of -$1.06. EPS for the following year is -$1.33, with 8 analysts recommending between -$1.16 and -$1.57.
Revenue Estimates
7 analysts predict $8.24M in revenue for the current quarter. It ranges from a high estimate of $10.8M to a low estimate of $6M. As of the current estimate, Tango Therapeutics Inc’s year-ago sales were $6.41M, an estimated increase of 28.50% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $7.92M, an increase of 37.40% over than the figure of $28.50% in the same quarter last year. There is a high estimate of $9.1M for the next quarter, whereas the lowest estimate is $6.25M.
A total of 7 analysts have provided revenue estimates for TNGX’s current fiscal year. The highest revenue estimate was $41.9M, while the lowest revenue estimate was $34.6M, resulting in an average revenue estimate of $38.63M. In the same quarter a year ago, actual revenue was $24.86M, up 55.40% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $30.34M in the next fiscal year. The high estimate is $39.5M and the low estimate is $21M. The average revenue growth estimate for next year is down -21.50% from the average revenue estimate for this year.
